PBH Stock Analysis: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$47.32
1.27 (2.76%)
▲
5d:
-0.38%
30d:
-1.42%
90d:
-23.68%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PBH trading at deep discount. Market pricing in -7.0% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: PBH trading at deep discount. Market pricing in -7.0% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$74.28
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$46.12
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $47.32, which is considered fair relative to its 30-day fair value range of $46.10 to $48.18. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.9) compared to its historical average (12.3). Remarkably, the market is currently pricing in an annual earnings decline of 7.0% over the next few years. This pessimistic expectation contrasts with the company's recent 12.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PBH is in a strong downtrend. Immediate support is located at $45.22, while resistance sits at $49.54.
Market Sentiment: PBH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $66.80 (+41.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PBH is in a strong downtrend. Immediate support is located at $45.22, while resistance sits at $49.54.
Market Sentiment: PBH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $66.80 (+41.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$46.10 -
$48.18
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.2% below Wall St target ($66.80)
Trading Range Analysis
30-Day Trading Range
$46.10 -
$48.18
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$45.22
Resistance Level
$49.54
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.88
Wall Street Target
$66.80
(+41.2%)
Revenue Growth (YoY)
-5.0%
Earnings Growth (YoY)
12.4%
Profit Margin
17.5%
Valuation Discount vs History
-7.0% cheaper
PE vs Historical
9.9 vs 12.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.0%
(market-implied from PE analysis)
1-Year Target
$44.01
(-7%)
2-Year Target
$40.93
(-14%)
3-Year Target
$38.06
(-20%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$47.38
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 5.5%)
$122.40
(+159%)
Base:
(SPY PE: 9.9, Growth: 5.5%)
$55.53
(+17%)
Bear:
(PE: 8.4, Growth: 5.5%)
$47.20
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 11.78 | Current EPS (TTM): $3.91
Bull Case
$62.04
(+31%)
Analyst growth 22.5%, PE expands to 13.0
Base Case
$56.40
(+19%)
Market implied 22.5%, PE stable at 11.8
Bear Case
$31.31
(-34%)
Severe decline -20.0%, PE contracts to 10.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.9 to 12.3
Stabilization Target:
$58.90
(+24.5%)
PE Expansion Potential:
+24.5%
Share & Embed Analysis
Last updated: June 24, 2026 9:26 PM ET
Data refreshes hourly during market hours. Next update: 10:26 PM
Data refreshes hourly during market hours. Next update: 10:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeffrey Zerillo
SELL
1000 shares
2026-02-11
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
